See more : PUNCTUAL TRADING LTD. (PUNCTRD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Zymergen Inc. (ZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymergen Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Kuniko Limited (KNI.AX) Income Statement Analysis – Financial Results
- Property & Building Corp. Ltd. (PTBL.TA) Income Statement Analysis – Financial Results
- Legible Inc. (READ.CN) Income Statement Analysis – Financial Results
- Aura Renewable Acquisitions plc (ARA.L) Income Statement Analysis – Financial Results
- Atai Life Sciences N.V. (ATAI) Income Statement Analysis – Financial Results
Zymergen Inc. (ZY)
About Zymergen Inc.
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 16.74M | 13.28M | 15.42M |
| Cost of Revenue | 69.72M | 84.82M | 102.64M |
| Gross Profit | -52.98M | -71.53M | -87.22M |
| Gross Profit Ratio | -316.42% | -538.50% | -565.67% |
| Research & Development | 159.12M | 90.85M | 50.72M |
| General & Administrative | 83.01M | 60.08M | 61.25M |
| Selling & Marketing | 23.65M | 18.63M | 24.14M |
| SG&A | 106.66M | 78.70M | 85.39M |
| Other Expenses | 175.51M | 0.00 | 0.00 |
| Operating Expenses | 265.78M | 169.56M | 136.10M |
| Cost & Expenses | 335.50M | 254.37M | 238.74M |
| Interest Income | 64.00K | 492.00K | 4.92M |
| Interest Expense | 14.71M | 10.96M | 2.94M |
| Depreciation & Amortization | 20.70M | 18.71M | 15.20M |
| EBITDA | -326.33M | -232.58M | -218.65M |
| EBITDA Ratio | -1,949.08% | -1,750.80% | -1,418.08% |
| Operating Income | -347.03M | -241.09M | -237.11M |
| Operating Income Ratio | -2,072.68% | -1,814.88% | -1,537.80% |
| Total Other Income/Expenses | -14.71M | -21.15M | 318.00K |
| Income Before Tax | -361.73M | -262.24M | -236.80M |
| Income Before Tax Ratio | -2,160.51% | -1,974.13% | -1,535.74% |
| Income Tax Expense | 51.00K | -49.00K | 8.00K |
| Net Income | -361.79M | -262.19M | -236.80M |
| Net Income Ratio | -2,160.81% | -1,973.76% | -1,535.79% |
| EPS | -4.87 | -2.68 | -2.42 |
| EPS Diluted | -4.87 | -2.68 | -2.42 |
| Weighted Avg Shares Out | 74.31M | 97.94M | 97.94M |
| Weighted Avg Shares Out (Dil) | 74.31M | 97.94M | 97.94M |
SEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales Prospects
Washington, D.C.--(Newsfile Corp. - September 13, 2024) - The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for...
Ginkgo Bioworks Completes Acquisition of Zymergen
BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen.
ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zymergen Inc. (NasdaqGS: ZY) to Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)....
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hanger, Inc....
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Gemini Therapeutics,...
Investor Alert - The M&A Class Action Firm Announces the Investigation of Zymergen Inc. - ZY
NEW YORK , July 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates IEA, ZY, FLAC
NEW YORK , July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Infrastructure & Energy...
SHAREHOLDER ALERT: Weiss Law Investigates Infrastructure and Zymergen Inc.
NEW YORK , July 25, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY), connected with the proposed acquisition...
Why Ginkgo Bioworks (DNA) Is Buying Zymergen For $300 Million
Ginkgo Bioworks (DNA) announced it entered into a definitive agreement under which Ginkgo will acquire Zymergen. These are the details.
Shareholder Alert: Ademi LLP investigates whether Zymergen Inc. has obtained a Fair Price in its transaction with Ginkgo
MILWAUKEE , July 25, 2022 /PRNewswire/ -- Ademi LLP is investigating Zymergen (NASDAQ: ZY) for possible breaches of fiduciary duty and other violations of law in its transaction with Ginkgo. Click here to learn how to join the action: https://www.ademilaw.com/case/zymergen-inc-0 or call...
Source: https://incomestatements.info
Category: Stock Reports